Clinical Trial

Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn about the effects of a higher dose of ncabozantinib in patients with advanced renal cell carcinoma who have progressed on or after receiving cabozantinib treatment.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-07-03; most recent amendment 2025-10-08.
Status change: Not Yet Recruiting → Recruiting 2023-12-20
Trial Details
NCT Number NCT05931393
Lead Sponsor University of Texas Southwestern Medical Center
Collaborators: Exelixis
Conditions RCC, Renal Cell Carcinoma
Enrollment 18 participants
Start Date 2023-12-20
Primary Completion 2026-09-01 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-10-10